TransThera Sciences (Nanjing) (FRA:J8J) EBIT: €-35.81 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8J TransThera Sciences (Nanjing) Inc FRA:J8J
20 GF Score
Price €1.05
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) EBIT?

TransThera Sciences (Nanjing) FRA:J8J -0.94% 20 EBIT is €-35.81 Mil as of Dec. 2025. GuruFocus rates FRA:J8J with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

TransThera Sciences (Nanjing)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-20.98 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-35.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TransThera Sciences (Nanjing)'s annualized ROC % for the quarter that ended in Dec. 2025 was -610.20%. TransThera Sciences (Nanjing)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,954.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TransThera Sciences (Nanjing)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9.04%.

TransThera Sciences (Nanjing)  (FRA:J8J) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TransThera Sciences (Nanjing)'s annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-42.284 * ( 1 - 0% )/( (7.402 + 6.457)/ 2 )
=-42.284/6.9295
=-610.20 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=83.66 - 11.195 - ( 76.778 - max(0, 13.312 - 78.375+76.778))
=7.402

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=66.192 - 14.711 - ( 59.309 - max(0, 15.706 - 60.73+59.309))
=6.457

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

TransThera Sciences (Nanjing)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-41.966/( ( (3.18 + max(-11.449, 0)) + (1.115 + max(-14.365, 0)) )/ 2 )
=-41.966/( ( 3.18 + 1.115 )/ 2 )
=-41.966/2.1475
=-1,954.18 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.031 + 1.512) - (11.195 + 0 + 1.797)
=-11.449

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.026 + 1.115) - (14.711 + 0 + 0.795)
=-14.365

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TransThera Sciences (Nanjing)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-35.809/395.918
=-9.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) EBIT Related Terms

TransThera Sciences (Nanjing) EBIT Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) EBIT Chart

TransThera Sciences (Nanjing) Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-44.07 -35.99 -35.87

TransThera Sciences (Nanjing) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBIT 0.00 -20.53 -14.97 -14.83 -20.98

FRA:J8J vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransThera Sciences (Nanjing) EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TransThera Sciences (Nanjing)'s EV-to-EBIT falls into.


FRA:J8J
20GF Score
TransThera Sciences (Nanjing) Inc FRA:J8J
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-35.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-35.81 Mil mean?
TransThera Sciences (Nanjing) (FRA:J8J) has a EBIT of €-35.81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TransThera Sciences (Nanjing).
Is TransThera Sciences (Nanjing)'s EBIT too high?
TransThera Sciences (Nanjing)'s current EBIT is €-35.81 Mil. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s EBIT compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s EBIT of €-35.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TransThera Sciences (Nanjing). TransThera Sciences (Nanjing)'s current EBIT is €-35.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current EBIT of €-35.81 Mil. The current EBIT is €-35.81 Mil. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current EBIT is €-35.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransThera Sciences (Nanjing) Business Description

Other Exchanges 02617:Hong Kong
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score

Get the complete analysis for FRA:J8J

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price